|Bid||61.55 x 900|
|Ask||61.88 x 800|
|Day's Range||61.26 - 62.70|
|52 Week Range||45.76 - 67.16|
|Beta (5Y Monthly)||0.62|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 05, 2021 - May 10, 2021|
|Forward Dividend & Yield||1.96 (3.20%)|
|Ex-Dividend Date||Dec 31, 2020|
|1y Target Est||75.13|
Growth stocks increase their sales by a double-digit percentage, are concerned with gobbling up market share, and aren't too focused on generating a profit. Meanwhile, value stocks are companies that have forward price-to-earnings multiples or price-to-earnings-growth ratios (PEG ratio) below the average of their industry or the broader market.
Agios' (AGIO) loss meets estimates in the fourth quarter of 2020 while revenues beat the same. Sale of leukemia drug, Tibsovo, rise both sequentially as well as year over year. Shares down.
Bristol Myers Squibb topped fourth-quarter expectations in February and cancer drug Opdivo returned to growth. But BMY stock floundered following the report. Is Bristol Myers stock a buy?